Skip to content

Intellia Therapeutics, Inc.

NTLA· NasdaqCore metricsCIK 1652130

In vitro & in vivo diagnostic substances19 peers

Last sale
Nov 12, 2026 · -7.54%
Market cap
$1.48B
140.36M shares
Filings
726
$7.16M
Q3 2026+16.9% FY25 yoy
-$127.49M
Q3 2026N/M FY25 yoy
-$122.33M
Q3 2026N/M FY25 yoy
-$288.67M
Q3 2026derivedN/M FY25 yoy
-$0.91
Q3 2026N/M FY25 yoy
$156.10M
Q3 2026−17.8% FY25 yoy
$1.48B
—
28.0×
2.4×
-24.18%
—

Twelve months to Sep 30, 2026 · derived

Price

$10.55+3.63%+$0.37past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$67.67MFY 2025
$67.67M0FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$67,671,000reported
FY 20242024-12-31$57,877,000reported
FY 20232023-12-31$36,275,000reported
FY 20222022-12-31$52,121,000reported
FY 20212021-12-31$33,053,000reported
FY 20202020-12-31$57,994,000reported
FY 20192019-12-31$43,103,000reported
FY 20182018-12-31$30,434,000reported
FY 20172017-12-31$26,117,000reported
FY 20162016-12-31$16,479,000reported

In vitro & in vivo diagnostic substances

Intellia Therapeutics, Inc. is the 6th largest of the 20 covered companies the SEC files under this code, by revenue. SIC 2835

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Intellia Therapeutics, Inc. · CIK 1652130 · Engraved from SEC EDGAR